研究室のご紹介

臨床研究

日本小児がん研究グループ（JCCG/JPLSG）および、日本小児白血病研究会（JACLS）のメンバーとして、これらのグループが推進する臨床試験に積極的に関わっています。

特に急性リンパ性白血病については治療研究委員会の一員として、臨床試験の立案・運用に関わり、その成績の解析などにも関わってきました。また、小児がんの診療における適切な支持療法の確立にむけた臨床研究にも取り組んでいます。

その他に、日本ランゲルハンス細胞組織球症研究会 (JLSG)の事務局を務めています。

基礎研究

  1. 難治性造血器腫瘍の遺伝子異常の解析と新規治療標的の探索

    小児急性リンパ性白血病および骨髄性白血病の遺伝子解析とくに融合遺伝子の機能解析を行い、より良い治療法の確立を目指して研究を行っています。

  2. 難治性急性リンパ性白血病に対する新規CAR-T治療の開発
    乳児の急性リンパ性白血病に対するFLT3 CAR-Tによる治療など、新たなCAR-T細胞治療の開発を目指して研究を行っています。

研究メンバー

講師 大曽根眞也
助教 吉田秀樹
助教 眞弓あずさ
助教 末松正也
助教 田中誠治
特任講師 加納　原
大学院生 三野耕平
大学院生 内藤優樹

所属学会

  • 日本小児血液・がん学会
  • 日本血液学会
  • 日本造血・免疫細胞療法学会
  • 米国血液学会

学会認定施設

  • 日本小児血液・がん専門医研修施設
  • 日本血液学会血液研修施設
  • 日本造血・免疫細胞療法学会　移植施設認定基準　認定カテゴリー1

業績

  1. Ishida H, Arakawa Y, Hasegawa D, Usami I, Hashii Y, Arai Y, Nishiwaki S, Keino D, Kato K, Sato M, Yoshida N, Ozawa Y, Okada K, Hidaka M, Yuza Y, Tanaka M, Watanabe K, Takita J, Kosaka Y, Fujita N, Tanaka J, Sato A, Atsuta Y, Imamura T. Reduced-intensity allogeneic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol 2024; 103: 843-854.

  2. Yano M, Ishida H, Hara J, Kawaguchi H, Ito E, Moriya-Saito A, Hashii Y, Deguchi T, Miyamura T, Sato A, Hori H, Horibe K, Imamura T. Outcome of hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia not in remission enrolled in JACLS ALL-02. Int J Hematol 2023; 118: 364-373.

  3. Mayumi A, Imamura T, Yoshida H, Osone S, Yasuda T, Iehara T. Leukaemic cells expressing ETV6::FRK are sensitive to dasatinib in vivo. EJHaem 2023; 4: 751-755.

  4. Okamoto K, Imamura T, Tanaka S, Urata T, Yoshida H, Shiba N, Iehara T. The Nup98::Nsd1 fusion gene induces CD123 expression in 32D cells. Int J Hematol 2023; 118: 277-287.

  5. Ishida H, Imamura T, Tatebe Y, Ishihara T, Sakaguchi K, Suenobu S, Sato A, Hashii Y, Deguchi T, Takahashi Y, Hasegawa D, Miyamura T, Iguchi A, Kato K, Saito-Moriya A, Hara J, Horibe K. Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukemia receiving the Japan Association of Childhood Leukemia Study ALL-02 protocol. Br J Haematol 2023; 201: 1200-1208.

  6. Suematsu M, Yagyu S, Yoshida H, Osone S, Nakazawa Y, Sugita K, Imamura T, Iehara T. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement. Cancer Immunol Immunother 2023; 72: 957-968.

  7. Osone S, Shinoda K, Yamamoto N, Suzuki K, Yano M, Ishida Y, Saito Y, Sawada A, Sano H, Kato Y, Shinkoda Y, Kakazu M, Mori N, Mizutani S, Fukushima K. Current methods of preventing infectious diseas and managing febrile neutropenia in childhood cancer patients: a nationwide survey in Japan. Int J Clin Oncol 2023; 28: 331-340.

  8. Mayumi A, Tomii T, Kanayama T, Mikami T, Tanaka K, Ueno H, Yoshida H, Kato I, Kawamura M, Nakahata T, Takita J, Hosoi H, Imamura T. The combination of ruxolitinib and Bcl2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion. Cancer Gene Ther 2022; 29: 1930-1938.

  9. Oya S, Osone S, Yoshida M, Nishimoto S, Taura Y, Yoshida H, Miyachi M, Inaba T, Konishi E, Kato M, Imamura T, Iehara T. Identification of RCC1-LCK as a novel fusion gene in pediatric erythroid sarcoma. Pediatr Blood Cancer 2022; 69: e29848.

  10. Ishida H, Kato M, Kawahara Y, Ishimaru S, Najima Y, Kako S, Sato M, Hiwatari M, Noguchi M, Kato K, Koh K, Okada K, Iwasaki F, Kobayashi R, Igarashi S, Saito S, Takahashi Y, Sato A, Tanaka J, Hashii Y, Atsuta Y, Sakaguchi H, Imamura T. Prognostic factors of children and adolescents with T-cell acute lymphoblastic leukemia after allogeneic transplantation. Hematol Oncol 2022; 40: 457-468.

  11. Moriya K, Imamura T, Katayama S, Kaino A, Okamoto K, Yokoyama N, Uemura S, Kitazawa H, Sekimizu M, Hiramatsu H, Usami I, Ishida H, Hasegawa D, Hama A, Moriya-Saito A, Sato A, Sasahara Y, Suenobu S, Horibe K, Hara J. The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukemia treated with a Berlin-Frankfurt-Munster (BFM)95-based protocol. Br J Haematol 2022; 196: 1257-1261.

  12. Suematsu M, Yagyu S, Nagao N, Kubota S, Shimizu Y, Tanaka M, Nakazawa Y, Imamura T. PiggyBac transposon-mediated CD19 chimeric antigen receptor-T cells derived from CD45RA-positive peripheral blood mononuclear cells possess potent and sustained antileukemic function. Front Immunol 2022 Jan 27; 13: 770132.

  13. Urata T, Imamura T, Osone S, Muramatsu H, Takahashi Y, Hosoi H. Genetic study of Fanconi Anemia in infancy revealed FANCI mutations and defective ALDH2 variant: a case report. J Pediatr Hematol Oncol 2022; 44: e438-e441.

  14. Tomii T, Imamura T, Tanaka K, Kato I, Mayumi A, Soma E, Yano M, Sakamoto K, Mikami T, Morita M, Kiyokawa N, Horibe K, Adachi S, Nakahata T, Takita J, Hosoi H. Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model. Leukemia 2021; 35: 2978-2982.

  15. Ishida H, Yano M, Hasegawa D, Hori T, Hashii Y, Kato K, Deguchi T, Saito A, Sato A, Hori H, Horibe K, Imamura T. Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study. Int J Hematol. 2021; 113: 893-902.

  16. Kondo H, Kanayama T, Matsumura U, Urata T, Osone S, Imamura T, Inaba T, Hosoi H. Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules. Int J Hematol. 2021; 113: 616-617.

  17. Kanayama T, Imamura T, Mayumi A, Soma E, Sakamoto K, Hayakawa F, Tanizawa A, Kiyokawa N, Hosoi H. Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient. Int J Hematol 2020;. 112: 714-719.

  18. Hasegawa D, Imamura T, Yumura-Yagi K, Takahashi Y, Usami I, Suenobu SI, Nishimura S, Suzuki N, Hashii Y, Deguchi T, Moriya-Saito A, Kato K, Kosaka Y, Hirayama M, Iguchi A, Kawasaki H, Hori H, Sato A, Kudoh T, Nakahata T, Oda M, Hara J, Horibe K; Japan Association of Childhood Leukemia Study Group (JACLS). Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02. Blood Cancer J 2020;. 10: 23.